Deal Tracker · Regions

GCC pharma deals

48 pharma deals in GCC tracked by EPT — distribution, partnerships & licensing. Most active: ADCAN Pharma, Mubadala Bio, Department of Health – Abu Dhabi & AstraZeneca. Latest: Galenicum → Al Ittihad Drug Store (Distribution, 31 Oct 2026).

Browse deals

By region

MENA (53) · Africa (14) · CIS & Central Asia (10) · Southeast Asia (8) · Global (LMICs) (5) · Türkiye (4) · Global ex-US (1)

By deal type

Licensing (38) · Distribution (25) · Technology transfer / Localization (23) · Partnership / Collaboration (22) · M&A / Acquisition (16) · Equity / Investment (7) · Joint venture (5) · Supply / Manufacturing (5)

By company

ADCAN Pharma (11) · Mubadala Bio (8) · Hikma Pharmaceuticals (6) · Jamjoom Pharma (6) · Bio-Thera Solutions (5) · Avalon Pharma (4) · SPIMACO (4) · Groupe Saidal (4) · Department of Health – Abu Dhabi (3) · Roche (3) · Sanofi (3) · Taiba Healthcare (3) · Tabuk Pharmaceuticals (3) · Dar Al Dawa (3) · Kazakhstan Ministry of Health (3) · Galenicum (2) · DKSH (2) · Laprophan (2) · Adalvo (2) · Eva Pharma (2) · Rameda (2) · Menarini (2) · AstraZeneca (2) · MS Pharma (2) · LifePharma (2) · JCR Pharmaceuticals (2) · Gen İlaç (2) · Philex Pharmaceuticals (2) · Lotus Pharmaceutical (2) · Elpen (2) · Dhofar Pharmaceutical Industries (2) · CCL Pharmaceuticals (2) · Abdi İbrahim (2) · Nordic Pharma (2) · SaudiVax (2) · Novo Nordisk (2) · VACSERA (2) · Lifera (2) · Julphar (2)

By therapeutic area

Multi-therapy (34) · Oncology (19) · Metabolic / Diabetes (18) · Cardiovascular (13) · Vaccines (11) · Immunology / Inflammation (8) · Ophthalmology (4) · Rare / Orphan (4) · CNS / Neurology (3) · Consumer health (3) · Infectious Disease (3) · Respiratory (2) · Women's Health (2)